MIRA reports SKNY-1 reverses anxiety behavior in animal model, differentiating from older CB1 drugs

MIRA PHARMACEUTICALS, INC.

SKNY-1 reversed anxiety-like behavior in zebrafish induced by a CB1 activator, normalizing to control or better levels.
Prior results showed SKNY-1 achieved up to 30% weight loss, reversed nicotine craving, and preserved muscle mass in animal models.
SKNY-1 is designed to avoid CNS side effects that halted earlier CB1 drugs like rimonabant.
Company is preparing for shareholder approval for acquisition of SKNY Pharmaceuticals; expects to start IND-enabling studies.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.